A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs AUT 00206 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; First in man
  • Sponsors Autifony Therapeutics
  • Most Recent Events

    • 10 Jan 2017 Results assessing Mismatch Negativity (MMN) latency published in an Autifony Therapeutics Media Release
    • 01 Aug 2016 Status changed from recruiting to completed, as reported in an Autifony Therapeutics media release.
    • 27 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top